Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer,LabEx MAbImprove industrial workshop,July 27–28, 2017, Tours,France |
| |
| Authors: | Camille Martin André Pèlegrin Hervé Watier Marie-Claude Viaud-Massuard Nicolas Joubert |
| |
| Institution: | 1. Equipe 4 IMT GICC, Université Fran?ois Rabelais, Tours, Francecamille.martin-4@etu.univ-tours.fr;3. IRCM, Institut de Recherche en Cancérologie de Montpellier, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier, France;4. Equipe 1 FRAME GICC, Université Fran?ois Rabelais, Tours, France;5. Service d'Immunologie, CHRU de Tours, Tours, France;6. Equipe 4 IMT GICC, Université Fran?ois Rabelais, Tours, France |
| |
| Abstract: | The annual “Antibody Industrial Symposium”, co organized by LabEx MAbImprove, MabDesign and Polepharma, was held in Tours, France on June 27–28, 2017. The focus was on antibody-drug-conjugates (ADCs), new entities which realize the hope of Paul Ehrlich's magic bullet. ADCs result from the bioconjugation of a highly cytotoxic drug to a selective monoclonal antibody, which acts as a vector. Building on knowledge gained during the development of three approved ADCs, brentuximab vedotin (Adcetris®), ado trastuzumab emtansine (Kadcyla®) and inotuzumab ozogamicin (Besponsa®), and the many ADCs in development, this meeting addressed strategies and the latest innovations in the field from fundamental research to manufacturing. |
| |
| Keywords: | ADC bioconjugation immunoconjugate immunotherapy |
|
|
